Biophytis SA has announced that its ordinary and extraordinary general meeting convened on November 12, 2026, was unable to proceed due to a lack of quorum. This situation is significant as it underscores the challenges the company faces in engaging its shareholders effectively. The meeting, which required a 20% quorum for ordinary matters and 25% for extraordinary ones, saw only 12.46% of the share capital represented.

As a result, the company has decided to reconvene the meeting on November 27, 2026, at 2:00 p.m. at the Silver Innov Building in Ivry-sur-Seine, France. The agenda will remain the same as the original meeting, and a notice of the second meeting will be published in the BALO on November 16, 2026.

In an effort to ensure that the meeting can proceed with valid deliberations, Biophytis plans to request the appointment of an ad hoc representative by the President of the Paris Commercial Court. This proxy will represent absent shareholders and exercise their voting rights. The company aims to facilitate a more inclusive decision-making process, especially given the low turnout observed at the initial meeting.

Biophytis SA is a clinical-stage biotechnology company focused on developing drug candidates for age-related diseases. Its lead drug candidate, BIO101, is currently in various stages of development for muscular disorders, respiratory diseases, and obesity. The company operates from its headquarters in Paris, France, with additional offices in Cambridge, Massachusetts, and Brazil. Its common stock is listed on Euronext Growth Paris.

The upcoming reconvened meeting is critical for Biophytis as it seeks to move forward with its agenda, which includes the approval of financial statements and other key resolutions. The company will keep its shareholders informed of any significant developments as they arise.

For more information about Biophytis and its initiatives, shareholders can visit the company’s website.